Published in Circulation on May 16, 2012
The pathogenesis of cardiac fibrosis. Cell Mol Life Sci (2013) 1.96
A Computational Study of the Factors Influencing the PVC-Triggering Ability of a Cluster of Early Afterdepolarization-Capable Myocytes. PLoS One (2015) 1.42
IL-1 induces proinflammatory leukocyte infiltration and regulates fibroblast phenotype in the infarcted myocardium. J Immunol (2013) 1.14
MicroRNA-208a increases myocardial fibrosis via endoglin in volume overloading heart. PLoS One (2014) 0.94
Targeting endoglin, an auxiliary transforming growth factor β coreceptor, to prevent fibrosis and heart failure. Circulation (2012) 0.88
Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. Pulm Circ (2013) 0.84
The role of TGFβ1 and LRG1 in cardiac remodelling and heart failure. Biophys Rev (2015) 0.83
Oxidative stress, fibrosis, and early afterdepolarization-mediated cardiac arrhythmias. Front Physiol (2013) 0.82
Targeting BMP signalling in cardiovascular disease and anaemia. Nat Rev Cardiol (2015) 0.82
Biventricular remodeling in murine models of right ventricular pressure overload. PLoS One (2013) 0.81
Endoglin: a critical mediator of cardiovascular health. Vasc Health Risk Manag (2013) 0.81
Reducing endoglin activity limits calcineurin and TRPC-6 expression and improves survival in a mouse model of right ventricular pressure overload. J Am Heart Assoc (2014) 0.80
Conditional knockout of activin like kinase-1 (ALK-1) leads to heart failure without maladaptive remodeling. Heart Vessels (2017) 0.78
Suppressive effect of epigallocatechin-3-O-gallate on endoglin molecular regulation in myocardial fibrosis in vitro and in vivo. J Cell Mol Med (2016) 0.77
Endoglin haplo-insufficiency modifies the inflammatory response in irradiated mouse hearts without affecting structural and mircovascular changes. PLoS One (2013) 0.77
The TGF-β pathway mediates doxorubicin effects on cardiac endothelial cells. J Mol Cell Cardiol (2015) 0.76
Cardiosphere-Derived Cells Require Endoglin for Paracrine-Mediated Angiogenesis. Stem Cell Reports (2017) 0.75
L-Endoglin overexpression increases renal fibrosis after unilateral ureteral obstruction. PLoS One (2014) 0.75
Comparison of reendothelialization and neointimal formation with stents coated with antibodies against endoglin and CD34 in a porcine model. Drug Des Devel Ther (2015) 0.75
High soluble endoglin levels do not induce changes in structural parameters of mouse heart. Heart Vessels (2017) 0.75
Transforming growth factor β: A potential biomarker and therapeutic target of ventricular remodeling. Oncotarget (2017) 0.75
The Role of Endoglin in Myocardial Fibrosis. Acta Cardiol Sin (2017) 0.75
Prognostication in Different Heart Failure Phenotypes: The Role of Circulating Biomarkers. J Circ Biomark (2016) 0.75
TGF-beta signal transduction. Annu Rev Biochem (1998) 17.83
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2008) 15.35
BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med (2003) 7.91
Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet (1994) 6.50
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Defective angiogenesis in mice lacking endoglin. Science (1999) 4.40
The epidemiology of heart failure. Eur Heart J (1997) 4.31
Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet (2001) 4.12
ECM remodeling in hypertensive heart disease. J Clin Invest (2007) 4.03
TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res (2004) 3.20
Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation (2002) 3.20
Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem (1999) 2.77
Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation (1998) 2.77
Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation (2001) 2.76
A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest (1999) 2.64
TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res (2006) 1.77
Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure. Circ Res (2005) 1.62
Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res (2010) 1.56
Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res (2000) 1.54
Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol (2008) 1.52
Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res (2004) 1.49
Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem (2011) 1.48
TGF-beta is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS One (2009) 1.38
Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res (2004) 1.35
Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest (2010) 1.25
The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes? Physiology (Bethesda) (2011) 1.20
Adaptive and maladptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading. Circ Heart Fail (2009) 1.17
L- and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J Cell Sci (2008) 1.05
Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblasts. Eur J Heart Fail (2010) 1.02
17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. J Card Fail (2008) 1.02
Endoglin modulation of TGF-beta1-induced collagen synthesis is dependent on ERK1/2 MAPK activation. Cell Physiol Biochem (2006) 1.00
Expression of endoglin in human mesangial cells: modulation of extracellular matrix synthesis. Biochim Biophys Acta (2002) 0.97
Hemodynamic modulation of endocardial thromboresistance. Circulation (2006) 0.93
Endoglin expression regulates basal and TGF-beta1-induced extracellular matrix synthesis in cultured L6E9 myoblasts. Cell Physiol Biochem (2004) 0.91
Decreased metalloprotease 9 induction, cardiac fibrosis, and higher autophagy after pressure overload in mice lacking the transcriptional regulator p8. Am J Physiol Cell Physiol (2011) 0.89
Usefulness of soluble endoglin as a noninvasive measure of left ventricular filling pressure in heart failure. Am J Cardiol (2010) 0.85
Expression of extracellular matrix genes during myocardial recovery from heart failure after left ventricular assist device support. J Heart Lung Transplant (2009) 0.85
Isolation and characterisation of human cardiac fibroblasts from explanted adult hearts. Cell Tissue Res (1996) 0.84
Alternative splicing factor or splicing factor-2 plays a key role in intron retention of the endoglin gene during endothelial senescence. Aging Cell (2011) 0.84
Glyceryl trinitrate inhibits hypoxia-induced release of soluble fms-like tyrosine kinase-1 and endoglin from placental tissues. Am J Pathol (2011) 0.82
Relationship between myocardial redox state and matrix metalloproteinase activity in patients on left ventricular assist device support. Circ J (2011) 0.77
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med (2004) 18.38
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
Statin-associated myopathy. JAMA (2003) 7.22
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med (2005) 6.50
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol (2005) 5.39
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol (2007) 4.93
Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation (2003) 4.51
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Molecular and cellular basis of cardiovascular gender differences. Science (2005) 4.37
Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (2011) 4.36
Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation (2007) 3.78
Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J (2003) 3.73
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med (2006) 3.72
Evidence-based guidelines for cardiovascular disease prevention in women. Circulation (2004) 3.39
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation (2005) 3.34
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA (2003) 3.25
Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest (2005) 3.22
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01
Tackling heart failure in the twenty-first century. Nature (2008) 2.93
Systolic improvement and mechanical resynchronization does not require electrical synchrony in the dilated failing heart with left bundle-branch block. Circulation (2002) 2.88
Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res (2005) 2.79
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol (2008) 2.77
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int (2012) 2.74
Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia. Hypertension (2013) 2.70
Optimal left ventricular endocardial pacing sites for cardiac resynchronization therapy in patients with ischemic cardiomyopathy. J Am Coll Cardiol (2010) 2.66
Pathogenesis of preeclampsia. Annu Rev Pathol (2010) 2.66
Cardiac magnetic resonance assessment of dyssynchrony and myocardial scar predicts function class improvement following cardiac resynchronization therapy. JACC Cardiovasc Imaging (2008) 2.64
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension (2007) 2.62
Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol (2006) 2.61
Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med (2012) 2.59
Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension (2006) 2.59
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol (2005) 2.53
High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation (2008) 2.47
Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science (2002) 2.45
Association between statin-associated myopathy and skeletal muscle damage. CMAJ (2009) 2.41
Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation (2005) 2.38
PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest (2005) 2.36
Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med (2003) 2.33
Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Crit Care Med (2012) 2.32
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol (2014) 2.30
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A (2005) 2.25
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA (2006) 2.24
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension (2005) 2.22
Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol (2002) 2.22
The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation (2005) 2.19
Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res (2004) 2.19
Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function. Endocrinology (2014) 2.17
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
Effect of soy protein from differently processed products on cardiovascular disease risk factors and vascular endothelial function in hypercholesterolemic subjects. Am J Clin Nutr (2007) 2.15
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res (2009) 2.11
Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA (2003) 2.10
Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) (2009) 2.10
Cardiac dyssynchrony analysis using circumferential versus longitudinal strain: implications for assessing cardiac resynchronization. Circulation (2005) 2.09
Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy. Circulation (2009) 2.09
Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol (2009) 2.09
Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol (2007) 2.07
HRT and the young at heart. N Engl J Med (2007) 2.07
Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol (2005) 2.06
Impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J Am Coll Cardiol (2007) 2.05
Multiple reaction monitoring to identify site-specific troponin I phosphorylated residues in the failing human heart. Circulation (2012) 2.05
Preeclampsia and angiogenic imbalance. Annu Rev Med (2008) 2.05
Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res (2002) 2.05
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03
Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension (2006) 2.02
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens (2007) 2.01
Cardiac resynchronization therapy: Part 2--issues during and after device implantation and unresolved questions. J Am Coll Cardiol (2005) 1.98
Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol (2010) 1.95
Functional impact of rate irregularity in patients with heart failure and atrial fibrillation receiving cardiac resynchronization therapy. Eur Heart J (2004) 1.95
Dynamic changes in conduction velocity and gap junction properties during development of pacing-induced heart failure. Am J Physiol Heart Circ Physiol (2007) 1.94
Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. J Clin Invest (2011) 1.94
Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. Circulation (2011) 1.92
Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res (2005) 1.91
Molecular mechanisms of preeclampsia. Microvasc Res (2007) 1.90
PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest (2011) 1.88
Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovasc Res (2006) 1.88